Hetero-modification of TRAIL trimer for improved drug delivery and in vivo antitumor activities

Poor pharmacokinetics and resistance within some tumor cell lines have been the major obstacles during the preclinical or clinical application of TRAIL (tumor-necrosis-factor (TNF)-related apoptosis-inducing ligand). The half-life of TRAIL(114-281) (114 to 281 amino acids) was revealed to be no more...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Li-Qiang, Zhao, Wen-Bin, Lai, Jun, Ding, Ding, Wei, Xiao-Yue, Li, Yang-Yang, Liu, Wen-Hui, Yang, Xiao-Yue, Xu, Ying-Chun, Chen, Shu-Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4597189/
https://www.ncbi.nlm.nih.gov/pubmed/26445897
http://dx.doi.org/10.1038/srep14872

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4597189/
https://www.ncbi.nlm.nih.gov/pubmed/26445897
http://dx.doi.org/10.1038/srep14872

Ejemplares similares